CJC-1295 vs Tesamorelin: GHRH Analogue Comparison
GH-axis peptide comparison
CJC-1295 vs Tesamorelin.
Both compounds are GHRH receptor analogues that drive endogenous growth hormone release. The practical difference is pharmacokinetics — Tesamorelin produces sharp daily pulses, CJC-1295 No DAC produces 30-minute pulses, and CJC-1295 with DAC produces multi-day sustained elevation. The right choice depends on the GH-pattern your research needs.
Bottom line
Tesamorelin (FDA-approved) is the most clinically validated GHRH analogue with daily dosing. CJC-1295 No DAC is a research compound with similar pulsatile profile. CJC-1295 with DAC has a 7-10 day half-life producing sustained GH elevation. For pulsatile GH research, Tesamorelin or CJC No DAC. For sustained GH-axis activation, CJC with DAC.
Side-by-side comparison
| CJC-1295 (No DAC) | Tesamorelin |
Deep dive: CJC-1295 (No DAC)
CJC-1295 No DAC is a tetrasubstituted GHRH analogue with substitutions (D-Ala, Gln, Ala, Leu) that resist dipeptidyl peptidase-4 cleavage. Plasma half-life is approximately 30 minutes, producing pulsatile GH release after each subcutaneous administration.
The No DAC variant is most commonly used in research combined with a GHRP (typically Ipamorelin), with the two peptides activating GHRH and ghrelin receptors simultaneously to produce a synergistic GH pulse 2-3 times larger than either alone.
CJC-1295 lacks FDA approval and remains a research compound. Most published characterization uses subcutaneous administration with twice-daily dosing aligned to natural GH pulse timing (before sleep and either morning or post-exercise).
Read the full CJC-1295 (No DAC) research guide →
Deep dive: Tesamorelin
Tesamorelin (Egrifta) is a stabilized GHRH analogue developed by Theratechnologies and FDA-approved in 2010 for HIV-associated lipodystrophy. The N-terminal trans-3-hexenoyl modification extends plasma half-life from native GHRH’s seconds-to-minutes range to approximately 26 minutes.
The compound has the most extensive human safety database of any GHRH analogue, accumulated through years of clinical use in the HIV indication and ongoing research in MASLD, body composition, and cognitive applications. The 2 mg daily subcutaneous dose is the most-studied protocol across these applications.
Tesamorelin produces visceral-adipose-tissue-specific reductions through enhanced GH pulse pattern. The visceral specificity distinguishes it from broader anti-obesity compounds and makes it useful for research focused on visceral fat endpoints.
Read the full Tesamorelin research guide →
Which should you research?
If your research is in a clinical-adjacent context where regulatory approval and safety data matter, Tesamorelin is the more validated choice. The HIV lipodystrophy approval program produced thousands of patient-years of human exposure data.
If your research is specifically on GHRH + GHRP combination pharmacology, CJC-1295 No DAC paired with Ipamorelin is the most-studied research preparation. The dual-pathway synergy is the central feature of this research framework.
For research on visceral fat reduction or hepatic fat content specifically, Tesamorelin has the strongest body of literature. The MASLD research line is particularly well-developed.
For research that needs sustained (multi-day) GH-axis elevation, CJC-1295 with DAC modification (a different compound from the No DAC variant) is the relevant choice — its 7-10 day half-life produces sustained rather than pulsatile GH release.
Stack option
The combination of Tesamorelin and CJC-1295 No DAC + Ipamorelin can be researched together to capture both pulse patterns simultaneously. The mechanisms are complementary because Tesamorelin works through a GHRH receptor with a slightly different binding profile, and the parallel ghrelin pathway from Ipamorelin adds the third mechanism.
Frequently asked questions
What is the difference between CJC-1295 with DAC and without DAC?
The DAC (Drug Affinity Complex) modification binds the peptide to serum albumin, extending plasma half-life to 7-10 days. Without DAC, the half-life is approximately 30 minutes. DAC produces sustained GH elevation; No DAC produces pulsatile GH release that better matches natural physiology.
Can Tesamorelin and CJC-1295 be used together?
Yes, they can be combined in research. Both target the GHRH receptor, so the combination doesn’t add a fundamentally new mechanism, but the slightly different binding profiles and pharmacokinetic windows can produce complementary GH-pulse patterns. Most research uses one or the other as the GHRH analogue, often combined with a GHRP like Ipamorelin for a dual-pathway approach.
Why is Tesamorelin the only FDA-approved GHRH analogue in this class?
Tesamorelin’s development program produced sufficient safety and efficacy data in the HIV lipodystrophy indication for FDA approval in 2010. CJC-1295 has not had a comparable clinical development program. Approval is indication-specific and reflects the regulatory path the developer pursued.
Which produces more visceral fat reduction in research?
Tesamorelin has the strongest published data on visceral adipose tissue reduction specifically, from both the HIV lipodystrophy approval program and subsequent MASLD research. CJC-1295 has not been extensively studied with visceral-fat-specific endpoints; most CJC-1295 research focuses on general GH-axis activation and IGF-1 elevation rather than tissue-specific outcomes.
What dose ranges are typical for each?
Tesamorelin is most commonly used at 2 mg daily subcutaneous. CJC-1295 No DAC is typically 100-300 microgram per administration, given 1-3 times daily, often combined with Ipamorelin at similar doses.
References
- Falutz J, Allas S, Blot K, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. View source
- Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295. View source
- Stanley TL, Fourman LT, Feldpausch MN, et al. (2019). Effects of Tesamorelin on NAFLD in HIV. View source
Reviewed by
The Aeternum Labs Research Team
Compounds, COAs, and protocol design
The Aeternum Labs research team verifies every batch in our library against published purity and identity standards. Comparison guides summarize publicly available scientific literature and are reviewed for accuracy by team members trained in peptide biochemistry.
Research Disclaimer. All compounds discussed in this article are sold by Aeternum Labs for in vitro laboratory research purposes only. They are not intended for human or animal consumption, diagnosis, treatment, or prevention of any disease or condition. Information presented is summarized from publicly available scientific literature and should not be construed as medical advice.